MP0250: Preliminary Phase I data

Preliminary data from 15 patients with advanced or metastatic solid tumors in an open-label, dose-escalation, European Phase I trial showed that 0.5, 1.5, 4 and 8 mg/kg IV MP0250 every 2 weeks led to ...